% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Carceller:125607,
author = {F. Carceller and L. A. Fowkes and K. Khabra and L. Moreno
and F. Saran and A. Burford and A. Mackay and D. Jones$^*$
and V. Hovestadt$^*$ and L. V. Marshall and S. Vaidya and H.
Mandeville and N. Jerome and L. R. Bridges and R. Laxton and
S. Al-Sarraj and S. Pfister$^*$ and M. O. Leach and A. D. J.
Pearson and C. Jones and D.-M. Koh and S. Zacharoulis},
title = {{P}seudoprogression in children, adolescents and young
adults with non-brainstem high grade glioma and diffuse
intrinsic pontine glioma.},
journal = {Journal of neuro-oncology},
volume = {129},
number = {1},
issn = {1573-7373},
address = {Dordrecht [u.a.]},
publisher = {Springer Science + Business Media B.V},
reportid = {DKFZ-2017-01733},
pages = {109 - 121},
year = {2016},
abstract = {Pseudoprogression (PsP) is a treatment-related phenomenon
which hinders response interpretation. Its prevalence and
clinical impact have not been evaluated in
children/adolescents. We assessed the characteristics, risk
factors and prognosis of PsP in children/adolescents and
young-adults diagnosed with non-brainstem high grade gliomas
(HGG) and diffuse intrinsic pontine gliomas (DIPG). Patients
aged 1-21 years diagnosed with HGG or DIPG between 1995 and
2012 who had completed radiotherapy were eligible. PsP was
assessed according to study-specific criteria and correlated
with first-line treatment, molecular biomarkers and
survival. Ninety-one patients (47 HGG, 44 DIPG) were
evaluable. Median age: 10 years (range, 2-20). Eleven
episodes of PsP were observed in 10 patients (4 HGG, 6
DIPG). Rates of PsP: $8.5 \%$ (HGG); $13.6 \%$ (DIPG). Two
episodes of PsP were based on clinical findings alone; nine
episodes had concurrent radiological changes: increased size
of lesions (n = 5), new focal enhancement (n = 4).
Temozolomide, MGMT methylation or H3F3A mutations were not
found to be associated with increased occurrence of PsP. For
HGG, 1-year progression-free survival (PFS) was $41.9 \%$
no-PsP versus $100 \%$ PsP (p = 0.041); differences in
1-year overall survival (OS) were not significant. For DIPG,
differences in 1-year PFS and OS were not statistically
significant. Hazard ratio $(95 \%CI)$ of PsP for OS was
0.551 (0.168-1.803; p = 0.325) in HGG; and 0.308
(0.107-0.882; p = 0.028) in DIPG. PsP occurred in both
pediatric HGG and DIPG patients at a comparable rate to
adult HGG. PsP was associated with improved 1-yr PFS in HGG
patients. PsP had a protective effect upon OS in DIPG
patients.},
cin = {B062 / B060},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)B060-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:27180091},
doi = {10.1007/s11060-016-2151-8},
url = {https://inrepo02.dkfz.de/record/125607},
}